White-coat hypertension and albuminuria; lessons from the hisayama and ohasama studies

IMPLICATIONS OF WHITE-COAT HYPERTENSION Ambulatory blood pressure monitoring was used to create four categories of blood pressure, true normotension (NT), white-coat hypertension (WCHT),

masked hypertension (MHT), and sustained hypertension (SHT), from one simple office blood pressure measurement [1]. The Ohasama study reported that a general population with WCHT and MHT had

a higher incidence of mortality from cardiovascular disease (CVD) than the one with NT (Fig. 1a) [2]. Compared with the NT population, the WCHT population seemed to have a higher incidence

of CVD mortality (hazards ratio 1.54 (0.73–3.21)), whereas the SHT population had a much higher incidence than the WCHT population. However, a meta-analysis of the data, which included the

Ohasama study, failed to demonstrate the significance of WCHT [3]. This meta-analysis thus rendered the meaning of WCHT controversial. Recently, a new meta-analysis that analyzed 20,455

subjects across 23 cohort studies on an individual level demonstrated that WCHT was associated with a 38% increased risk of CVD and a 20% increase in total mortality [4]. Another

meta-analysis also supported a significant risk of cardiovascular events associated with WCHT [5]. Moreover, in chronic kidney disease patients, WCHT and MHT were also reported to be risk

factors for CVD [6]. At this point, the clinical evidence suggests that the risk of mortality and CVD events associated with WCHT lies between those with NT and SHT. The prevalence of WCHT

was 32.7%, as reported in the Spanish ambulatory blood pressure registry, whereas that of SHT was 44.5% [7]. The implications of WCHT have been evaluated from several perspectives in

relation to CVD and mortality [8]. The Hisayama study, one of the most famous cohort studies, reported that WCHT was associated with carotid atherosclerosis (Fig. 1b) [9]. In this report,

the average thickness of intima-media in cases of WCHT was the same as that for SHT, which was significantly higher than that in NT. This finding was supported by a meta-analysis [10].

Retinal vascular abnormalities in WCHT were reported to be the same as those in SHT [11]. Development of atherosclerosis induced by WCHT should result in SHT. Indeed, WCHT led to the

development of SHT at a higher rate than NT (odds ratio 2.51; _P_ < 0.0001) [12]. However, detailed clinical features remain unclear because the meaning of WCHT has only recently been

established. ALBUMINURIA IN WHITE-COAT HYPERTENSION In this current issue, the Hisayama cohort study reported that WCHT was associated with a significantly increased age- and sex-adjusted

prevalence of albuminuria, compared to NT (26.3 vs. 14.1%, _P_ < 0.001), although this research was from a cross-sectional study [13]. Interestingly, the effect of WCHT on the prevalence

of albuminuria was similar to the effect of WCHT on CVD events and carotid atherosclerosis (Fig. 1a, b). This consistent effect of WCHT on several atherosclerotic diseases could make the

pathogenicity of WCHT convincing. Albuminuria was basically considered to be the result of endothelial dysfunction, which means that albuminuria was considered to be the result of

hypertension. However, a slight increase in albuminuria within the normal range predicted hypertension in the future, suggesting that albuminuria might be the cause of hypertension [14]. At

this point, it is difficult to distinguish which is the causal factor, hypertension, or albuminuria [15]. With respect to WCHT, there is no consistent evidence supporting endothelial

dysfunction. Evaluation of endothelial function by brachial artery flow-mediated vasodilation has provided conflicting results [16, 17]. More directly, Oliveras et al. [18] failed to

demonstrate a relationship between albuminuria and WCHT. The effect on albuminuria associated with WCHT was similar to the effect on carotid atherosclerosis and CVD events, which may reflect

the relationship between WCHT and albuminuria, and more importantly, the pathogenicity of WCHT. MECHANISM BY WHICH WHITE-COAT HYPERTENSION IS ASSOCIATED WITH ALBUMINURIA The clinical

pathogenicity of WCHT itself was established recently [10]. Therefore, the mechanism by which WCHT causes an increase in CVD events, resulting in greater mortality, has ultimately remained

unknown [19, 20]. However, there are several mechanisms to consider that may explain why WCHT was associated with albuminuria (Fig. 2). WCHT was defined as an increase in blood pressure at

the doctor’s office, which obviously suggested that patients with WCHT had hypersensitive sympathetic nervous activity. Indeed, there are many reports that support this hypersensitive

activity in those with WCHT. Those with WCHT had significantly higher sympathetic nervous activity than those with NT, when measured by microneurography [21]. Those with WCHT had a higher

ratio of high-frequency to low-frequency heart rate variability than those with NT [22, 23]. More directly, the WCHT group had a greater blood pressure response to mental stress than the NT

group [24]. In the first mechanism, this hypersensitive sympathetic activity was believed to be a strong risk factor for CKD, CVD, and mortality [25,26,27,28], just as this hypersensitive

activity may cause WCHT. In the second mechanism, those with WCHT often suffered from metabolic syndrome, as the Ohasama study reported [2]. Metabolic syndrome is also believed to have

strong causality in CVD and mortality, and it is considered to cause endothelial dysfunction, resulting in albuminuria. In the third mechanism, those with WCHT had a higher probability of

developing SHT than those with NT [12]. SHT is one of the most important risk factors for CVD, CKD, and albuminuria. Finally, it is possible that WCHT itself causes albuminuria, although

there is no evidence supporting this direct causality. Moreover, it remains unknown whether albuminuria in WCHT might result in the progression of CKD, whereas albuminuria is considered

causal in CKD because albuminuria has been associated with higher incidence of CVD and progression of CKD [29, 30]. The meaning of WCHT, including its association with albuminuria, will be

revealed in future studies. REFERENCES * Solak Y, Kario K, Covic A, Bertelsen N, Afsar B, Ozkok A, Wiecek A, Kanbay M. Clinical value of ambulatory blood pressure: Is it time to recommend

for all patients with hypertension?. Clin Exp Nephrol. 2016;20:14–22. Article  PubMed  Google Scholar  * Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H,

Satoh H, Imai Y. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll

Cardiol. 2005;46:508–15. Article  PubMed  Google Scholar  * Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true

normotension: a meta-analysis. J Hypertens. 2007;25:2193–8. Article  PubMed  CAS  Google Scholar  * Huang Y, Huang W, Mai W, Cai X, An D, Liu Z, Huang H, Zeng J, Hu Y, Xu D. White-coat

hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens. 2017;35:677–88. Article  PubMed  PubMed Central  CAS  Google Scholar  * Briasoulis A, Androulakis

E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016;34:593–9. Article  PubMed  CAS  Google Scholar  * Kushiro T,

Kario K, Saito I, Teramukai S, Sato Y, Okuda Y, Shimada K. Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease:

the HONEST Study. Hypertens Res. 2017;40:87–95. Article  PubMed  Google Scholar  * Gorostidi M, Vinyoles E, Banegas JR, de la Sierra A. Prevalence of white-coat and masked hypertension in

national and international registries. Hypertens Res. 2015;38:1–7. Article  PubMed  Google Scholar  * Cuspidi C, Rescaldani M, Tadic M, Sala C, Grassi G, Mancia G. White-coat hypertension,

as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis. J Hypertens. 2015;33:24–32. Article  PubMed  CAS  Google Scholar  * Fukuhara M,

Arima H, Ninomiya T, Hata J, Hirakawa Y, Doi Y, Yonemoto K, Mukai N, Nagata M, Ikeda F, Matsumura K, Kitazono T, Kiyohara Y. White-coat and masked hypertension are associated with carotid

atherosclerosis in a general population: the Hisayama study. Stroke. 2013;44:1512–7. Article  PubMed  CAS  Google Scholar  * Cuspidi C, Sala C, Tadic M, Rescaldani M, Grassi G, Mancia G.

_I_s white-coat hypertension a risk factor for carotid atherosclerosis? A review and meta-analysis. Blood Press Monit. 2015;20:57–63. PubMed  Google Scholar  * Triantafyllou A, Doumas M,

Anyfanti P, Gkaliagkousi E, Zabulis X, Petidis K, Gavriilaki E, Karamaounas P, Gkolias V, Pyrpasopoulou A, Haidich AB, Zamboulis C, Douma S. Divergent retinal vascular abnormalities in

normotensive persons and patients with never-treated, masked, white coat hypertension. Am J Hypertens. 2013;26:318–25. Article  PubMed  CAS  Google Scholar  * Mancia G, Bombelli M, Facchetti

R, Madotto F, Quarti-Trevano F, Polo Friz H, Grassi G, Sega R. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226–32. Article  PubMed 

CAS  Google Scholar  * Hata J, Fukuhara M, Sakata S, Arima H, Hirakawa Y, Yonemoto K, Mukai N, Kitazono T, Kiyohara Y, Ninomiya T. White-coat and masked hypertension are associated with

albuminuria in a general population: the Hisayama Study. Hypertens Res. 2017;40:937–43. Article  PubMed  CAS  Google Scholar  * Hirayama A, Konta T, Hozawa A, Kawasaki R, Watanabe T, Shibata

Y, Kayama T, Fukao A, Kubota I. Slight increase in urinary albumin excretion within the normal range predicts incident hypertension in a community-based Japanese population: the Takahata

study. Hypertens Res. 2015;38:56–60. Article  PubMed  CAS  Google Scholar  * Nagasawa Y, Hasuike Y, Nanami M, Kuragano T, Nakanishi T. Albuminuria and hypertension: the chicken or the egg?.

Hypertens Res. 2015;38:8–10. Article  PubMed  Google Scholar  * Pierdomenico SD, Cipollone F, Lapenna D, Bucci A, Cuccurullo F, Mezzetti A. Endothelial function in sustained and white coat

hypertension. Am J Hypertens. 2002;15:946–52. Article  PubMed  CAS  Google Scholar  * Gomez-Cerezo J, Rios Blanco JJ, Suarez Garcia I, Moreno Anaya P, Garcia Raya P, Vazquez-Munoz E, Barbado

Hernandez FJ. Noninvasive study of endothelial function in white coat hypertension. Hypertension. 2002;40:304–9. Article  PubMed  CAS  Google Scholar  * Oliveras A, Armario P, Hernandez-Del

Rey R, Arroyo JA, Poch E, Larrousse M, Roca-Cusachs A, de la Sierra A. Urinary albumin excretion is associated with true resistant hypertension. J Hum Hypertens. 2010;24:27–33. Article 

PubMed  CAS  Google Scholar  * Martin CA, McGrath BP. White-coat hypertension. Clin Exp Pharmacol Physiol. 2014;41:22–9. Article  PubMed  CAS  Google Scholar  * Cuspidi C, Sala C, Grassi G,

Mancia G. White Coat Hypertension: to Treat or Not to Treat?. Curr Hypertens Rep. 2016;18:80. Article  PubMed  CAS  Google Scholar  * Grassi G, Seravalle G, Trevano FQ, Dell’oro R, Bolla G,

Cuspidi C, Arenare F, Mancia G. Neurogenic abnormalities in masked hypertension. Hypertension. 2007;50:537–42. Article  PubMed  CAS  Google Scholar  * Fagard RH, Stolarz K, Kuznetsova T,

Seidlerova J, Tikhonoff V, Grodzicki T, Nikitin Y, Filipovsky J, Peleska J, Casiglia E, Thijs L, Staessen JA, Kawecka-Jaszcz K. Sympathetic activity, assessed by power spectral analysis of

heart rate variability, in white-coat, masked and sustained hypertension versus true normotension. J Hypertens. 2007;25:2280–5. Article  PubMed  CAS  Google Scholar  * Madsen LB, Rasmussen

JK, Moller DS, Nyvad O, Pedersen EB. Heart rate variability in white-coat hypertension. Blood Press Monit. 2008;13:65–71. Article  PubMed  Google Scholar  * Martin CA, Cameron JD, Chen SS,

McGrath BP. Two hour glucose post loading: a biomarker of cardiovascular risk in isolated clinic hypertension. J Hypertens. 2011;29:749–57. Article  PubMed  CAS  Google Scholar  *

Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013;113:739–53. Article  PubMed  CAS  Google Scholar  * Gillman MW,

Kannel WB, Belanger A, D’Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993;125:1148–54. Article  PubMed  CAS  Google

Scholar  * Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J

Nephrol. 2009;22:208–15. PubMed  Google Scholar  * Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A,

Stancanelli B, Malatino LS. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354–9. Article  PubMed

  CAS  Google Scholar  * Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated

glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81. Article  Google

Scholar  * Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney

disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28. Article  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of

Internal Medicine, Division of Kidney and Dialysis, Hyogo College of Medicine, 1-1, Mukogawa-Cho, Nishinomiya, 663-8501, Japan Yasuyuki Nagasawa, Aritoshi Kida, Yukiko Hasuike, Takahiro

Kuragano & Takeshi Nakanishi Authors * Yasuyuki Nagasawa View author publications You can also search for this author inPubMed Google Scholar * Aritoshi Kida View author publications You

can also search for this author inPubMed Google Scholar * Yukiko Hasuike View author publications You can also search for this author inPubMed Google Scholar * Takahiro Kuragano View author

publications You can also search for this author inPubMed Google Scholar * Takeshi Nakanishi View author publications You can also search for this author inPubMed Google Scholar

CORRESPONDING AUTHOR Correspondence to Yasuyuki Nagasawa. ETHICS DECLARATIONS CONFLICT OF INTEREST The authors declare that they have no conflict of interest. RIGHTS AND PERMISSIONS Reprints

and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Nagasawa, Y., Kida, A., Hasuike, Y. _et al._ White-coat hypertension and albuminuria; lessons from the Hisayama and Ohasama studies.

_Hypertens Res_ 41, 483–485 (2018). https://doi.org/10.1038/s41440-018-0036-2 Download citation * Received: 29 September 2017 * Revised: 31 October 2017 * Accepted: 31 October 2017 *

Published: 18 April 2018 * Issue Date: July 2018 * DOI: https://doi.org/10.1038/s41440-018-0036-2 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this

content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative